Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing.
New York, NY, and Tel Aviv, ISRAEL, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing. Provista is able to test for both COVID-19 and MonkeyPox from the same saliva sample. The expansion of onsite sample collection support for schools to include MonkeyPox is designed for a situation where a school has a confirmed MonkeyPox case, whether from staff or students, and there is a desire from school administrators to screen staff and students entering the school in order to contain potential MonkeyPox outbreaks. In these situations, it is highly recommended that schools simultaneously test for COVID-19 in order to minimize the potential that students could be simultaneously infected with COVID and MonkeyPox, as has recently been reported can occur. The service is initially available in select Georgia and New Jersey districts where Provista already has established capabilities. The Company plans to expand the jurisdictions in which this service is available through sample collection partnerships in the near future.
“We have been moving extremely fast to get ahead of the curve in MonkeyPox testing, and providing access to screening programs is the obvious next step to help facilitate the containment of outbreaks in school settings,” said Gerald E. Commissiong, President & CEO of Todos Medical. “While the federal government’s response to the MonkeyPox public health emergency continues to evolve, we are focused on the practical implications of what this could mean for real people in our communities. COVID-19 remains a major threat to health, especially in children who appear to be at higher risk of developing Long COVID (1 in 4 for children vs. 1 in 5 for adults), and as such it is prudent to conduct screening for COVID-19 alongside any MonkeyPox outbreak. This has the dual benefit of pinpointing individuals who may be at greatest risk of poor outcomes due to dual infections, and has the benefit of likely lowering COVID-19 transmission in schools by identifying asymptomatic cases of individuals who were previously spreading SARS-CoV-2. Given that the expectation is weekly screening for MonkeyPox testing for 2-3 weeks after a confirmed case is identified in a school setting, the simultaneous benefit of substantially lowering within school transmission has obvious long-term benefits for the health of the school population. We are proud to be able to bring this innovative solution to market so rapidly to help protect our communities.”
For more information on MonkeyPox Testing or case study enrollment please contact: customerservice@provistadx.com.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at www.provistadx.com.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL protease – based diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid™ in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, while also developing the 3CL protease diagnostic TolloTest™.
To purchase Tollovid please visit Amazon or www.MyTollovid.com. For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch
CFO
Todos Medical
917-983-4229 x 104
Dan.h@todosmedical.com
Todos Press Contact:
Kyle Kappmeier
JConnelly
Vice President
973-975-7827
kkapmeier@jconnelly.com
